CVS Health Corp

• CVS Health rebounded after institutional buyers accumulated shares following a recent sell-off. • Third-quarter operating performance exceeded consensus estimates across revenue and adjusted earnings per share. • Management raised full-year adjusted earnings guidance and substantially boosted operating cash flow projections.

• Stryker faced share price pressure from margin compression and restructuring expenses. • Elective procedure volumes normalized alongside disciplined hospital capital equipment procurement. • Technical indicators show a buy signal with neutral RSI conditions.

• Intuitive Surgical declined due to valuation sensitivity and hospital capital spending scrutiny. • Institutional profit-taking and macroeconomic crosscurrents weighed on high-multiple growth equities. • The company reported annual revenue of $10.06 billion and net profit.

• UnitedHealth dropped due to rising medical utilization and compressed underwriting margins. • Regulatory scrutiny on Medicare Advantage and pharmacy benefits added sector-wide pressure. • The stock exhibits neutral technical indicators with an oversold Williams %R.

• Thermo Fisher faced downward pressure from macroeconomic challenges and life sciences headwinds. • Investors locked in gains following valuation consolidation and recent post-earnings strength. • Technical indicators show neutral conditions with an RSI value of 51.696.

CVS Health plans to separate into two independent, publicly traded healthcare companies, with completion expected in the first half of 2028 subject to customary conditions.